PSMA for PET Imaging of Prostate Cancer

Main Article Content

Ananya Ruangma
Suphansa Kijprayoon
Suthatip Ngokpol

Abstract

18F-fluorodeoxyglucose (FDG or 18F-FDG) is the most widely used radiotracer forPositron Emission Tomography/Computed Tomography (PET/CT) imaging. However,using FDG for PET/CT imaging in prostate cancer is limited because a large fractionof prostate cancer shows limited FDG uptake. Previously, radiolabeled choline derivativesuch as 18F-fluorocholine and 11C-choline were considered as a more suitable alternativeto FDG for prostate cancer imaging. They are used as PET tracers for staging andrestaging of prostate cancer. Although the specificity of radiolabeled choline is quitehigh, the sensitivity is rather poor. Currently, targeting the prostate specific membraneantigen (PSMA) with molecular imaging agents has been increasingly investigated.PSMA is expressed in most prostate cancer and it is an ideal target for diagnosis andtreatment. There are many PSMA agents available nowadays. This article will givebrief overview about PSMA ligands for PET imaging and therapy of prostate cancer.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Ruangma A, Kijprayoon S, Ngokpol S. PSMA for PET Imaging of Prostate Cancer. BKK Med J [Internet]. 2018Sep.20 [cited 2020Sep.30];14(2):95. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/240855
Section
Reviews Article

References

1. Siegel R, Miller K, Jemal A. Cancer Statistic, 2017. CACancer J Clin 2017;67:7-30.
2. American Cancer Society. Cancer Facts & Figures 2018.Atlanta, Ga: American Cancer Society; 2018.
3. Gambhir SS, Czermin J, Schwimmer J, et al. A tabulatedsummary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
4. Bouchelouche K, Tagawa ST, Goldsmith SJ, et al. PET/CTImaging and Radioimmunotherapy of Prostate Cancer. SeminNucl Med. 2011;41:29-44.
5. Evangelista L, Guttilla A, Zatttoni F, et al. Utility of cholinepositron emission tomography/computed tomography forlymph node involvement identification in intermediate- tohigh-risk prostate cancer: a systematic literature review andmeta-analysis. Eur Urol. 2013;63:1040-8.
6. Silver DA, Pellicer I, Fair WR, et al. Prostate-specificmembrane antigen expression in normal and malignant humantissues. Clin Cancer Res. 1997;3:81-5
7. Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneityof prostate-specific membrane antigen (PSMA) expression inprostate carcinoma with distant metastasis. Path Oncol Res.2009;15:167-72.
8. Bostwick DG, Pacelli A, Blute M, et al. Prostate specificmembrane antigen expression in prostatic intraepithelialneoplasia and adenocarcinoma: a study of 184 cases. Cancer.1998;82:2256-61.
9. Troyer JK, Beckett ML, Wright GL. Detection and characterizationof the prostate-specific membrane antigen (PSMA) intissue extracts and body fluids. Int J Cancer. 1995;62:552-8.
10. Sterzing F, et al. 68Ga-PSMA-11 PET/CT: a new techniquewith high potential for the radiotherapeutic management ofprostate cancer patients. Eur J Nucl Med Mol Imaging.2016;43:34-41.
11. Ghosh A, Heston W.D. Tumor target prostate specificmembrane antigen (PSMA) and its regulation in prostatecancer. J Cell Biochem. 2004;91:528-39.
12. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonalantibodies to a new antigenic marker in epithelial prostaticcells and serum of prostatic cancer patients.Anticancer Res.1987;7:927-35.
13. Foss CA, et al. Radiolabeled small-molecule ligands forprostate-specific membrane antigen; in vivo imaging inexperimental models of prostate cancer. Clin Cancer Res.2005;11:4022-8.14.
14. Hillier S. M. et al. Preclinical evaluation of novelglutamate-urea-lysine analogues that target prostate-specificmembrane antigen as molecular imaging pharmaceuticals forprostate cancer. Cancer Res. 2009;69:6932-40.
15. Kularatne SA, Zhou Z, Yang J, et al. Design, synthesis andpreclinical evaluation of prostate-specific membrane antigentargeted 99mTc-radioimaging agents. Mol Pharm. 2009;6:790-800.
16. Rowe S. P, et al. PSMA-Based [18F]DCFPyL PET/CT IsSuperior to Conventional Imaging for Lesion Detection inPatients with Metastatic Prostate Cancer. Mol Imaging Biol.2016;18:411-9.
17. Chen Y. et al. 2-(3-{1-carboxy-5-[(6-[19F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyl, a PSMA-based PET imaging agent for prostatecancer. Clin Cancer Res. 2011;17:7645-53.
18. Giesel FL, et al. F-18 labelled PSMA-1007: biodistribution,radiation dosimetry and histopathological validation of tumorlesions in prostate cancer patients. Eur J Nucl Mol Imaging.2017;44:678-88.
19. Benerjee SR. et al. A modular strategy to prepare multivalentinhibitors of prostate-specific membrane antigen (PSMA).Oncotarget. 2011;2:1244-53.
20. Afshar-Oromieh A. et al. The diagnostic value of PET/CTimaging with the (68)Ga-labelled PSMA ligand HBED-CCin the diagnosis of recurrent prostate cancer. Eur J Nucl MedMol Imaging. 2015;42:197-209.
21. Kallur KG., et al. Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer. Indian J Nucl Med. 2017;32:110-7.
22. Uprimny C, et al. Early PET imaging with [68]Ga-PSMA-11increases the detection rate of local recurrence in prostatecancer patients with biochemical recurrence. Eur J Nucl MedMol Imaging. 2017; 44:1647-55.
23. Kesch C, et al. 68Ga or 18F for Prostate Cancer Imaging? JNucl Med. 2017;58:687-8.
24. Rowe SP., et al. PET imaging of prostate-specific membraneantigen in prostate cancer: current state of the art and futurechallenges. Prostate Cancer Prostatic Dis. 2016;19:223-30.
25. Lutje S, et al. PSMA Ligands for Radionuclide Imaging andTherapy of Prostate Cancer: Clinical Status. Theranostics.2015;5:1388-401.
26. Chen Y, et al. Synthesis and biological evaluation of lowmolecular weight fluorescent imaging agents for the prostatespecificmembrane antigen. Bioconjug Chem 2012; 23:2377-85.
27. Eder M, et al. Tetrafluorophenolate of HBED-CC: A versatileconjugation agent for 68Ga-labeled small recombinant antibodies.Eur J Nucl Med Mol Imaging 2008;35:1878-86.
28. Eberhan T, et al. Development of a Single Vial Kit Solutionfor Radiolabeling of 68Ga-DKFZ-PSMA-11 and ItsPerformance in Prostate Cancer Patients. Molecules. 2015;20:14860-78.
29. Satpati D, et al. Convenient Preparation of [(68)Ga]DKFZPSMA-11 Using a Robust Single-Vial Kit and Demonstrationof Its Clinical Efficacy. Mol Imaging Biol. 2016; 18:420-7.
30. Weineisen M, Simecek J, Schottelius M, et al. Synthesis andpreclinical evaluation of DOTAGA-conjugated PSMA ligandsfor functional imaging and endoradiotherapy of prostatecancer. EJNMMI Res. 2014;4:63.
31. Ahmadzadehfar H, Eppard E, Kürpig S et al. Therapeuticresponse and side effects of repeated radioligand therapy with177Lu-PSMA-DKFZ-617 of castrate resistant metastaticprostate cancer. Oncotarget 2016;7:12477-88.
32. Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. Germanmulticenter study investigating 177Lu-PSMA-617 radioligandtherapy in advanced prostate cancer patients. J Nucl Med2017;58:85-90.